Verastem, Inc.

NasdaqCM:VSTM Stock Report

Market Cap: US$174.9m

Verastem Valuation

Is VSTM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VSTM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VSTM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VSTM's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VSTM?

Key metric: As VSTM is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VSTM. This is calculated by dividing VSTM's market cap by their current revenue.
What is VSTM's PS Ratio?
PS Ratio17.8x
SalesUS$10.00m
Market CapUS$174.91m

Price to Sales Ratio vs Peers

How does VSTM's PS Ratio compare to its peers?

The above table shows the PS ratio for VSTM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average12.5x
CRBU Caribou Biosciences
15.9x66.7%US$179.3m
EDIT Editas Medicine
3.3x15.2%US$195.6m
YMTX Yumanity Therapeutics
29.7xn/aUS$143.6m
STRO Sutro Biopharma
1.3x27.4%US$208.6m
VSTM Verastem
17.8x59.3%US$174.9m

Price-To-Sales vs Peers: VSTM is expensive based on its Price-To-Sales Ratio (17.8x) compared to the peer average (6.8x).

Price to Sales Ratio vs Industry

How does VSTM's PS Ratio compare vs other companies in the US Biotechs Industry?

129 CompaniesPrice / SalesEstimated GrowthMarket Cap
GILD Gilead Sciences
4x2.4%US$111.86b
BIIB Biogen
2.4x1.3%US$23.03b
MRNA Moderna
3.1x6.8%US$14.72b
INCY Incyte
3.4x8.9%US$13.56b
VSTM 17.8xIndustry Avg. 9.7xNo. of Companies129PS01632486480+
129 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: VSTM is expensive based on its Price-To-Sales Ratio (17.8x) compared to the US Biotechs industry average (9.6x).

Price to Sales Ratio vs Fair Ratio

What is VSTM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VSTM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio17.8x
Fair PS Ratio23x

Price-To-Sales vs Fair Ratio: VSTM is good value based on its Price-To-Sales Ratio (17.8x) compared to the estimated Fair Price-To-Sales Ratio (23x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VSTM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$4.00
US$11.13
+178.1%
29.3%US$15.00US$7.00n/a8
Nov ’25US$3.92
US$11.88
+202.9%
36.6%US$20.00US$7.00n/a8
Oct ’25US$2.82
US$11.88
+321.1%
36.6%US$20.00US$7.00n/a8
Sep ’25US$2.50
US$11.71
+368.6%
39.4%US$20.00US$7.00n/a7
Aug ’25US$2.43
US$14.07
+479.1%
34.7%US$20.00US$7.00n/a7
Jul ’25US$3.25
US$22.50
+592.3%
36.8%US$36.00US$13.00n/a7
Jun ’25US$3.96
US$22.50
+468.2%
36.8%US$36.00US$13.00n/a7
May ’25US$9.98
US$28.79
+188.4%
23.0%US$36.00US$17.50n/a7
Apr ’25US$11.73
US$28.79
+145.4%
23.0%US$36.00US$17.50n/a7
Mar ’25US$13.02
US$28.79
+121.1%
23.0%US$36.00US$17.50n/a7
Feb ’25US$12.25
US$28.79
+135.0%
23.0%US$36.00US$17.50n/a7
Jan ’25US$8.14
US$29.44
+261.6%
21.9%US$36.00US$17.50n/a8
Dec ’24US$7.01
US$29.44
+319.9%
21.9%US$36.00US$17.50n/a8
Nov ’24US$6.31
US$30.50
+383.4%
24.4%US$39.00US$17.50US$3.927
Oct ’24US$8.13
US$30.50
+275.2%
24.4%US$39.00US$17.50US$2.827
Sep ’24US$9.86
US$32.08
+225.4%
21.4%US$39.00US$17.50US$2.506
Aug ’24US$10.98
US$36.83
+235.5%
24.3%US$54.00US$24.00US$2.436
Jul ’24US$7.44
US$40.67
+446.6%
30.4%US$60.00US$24.00US$3.256
Jun ’24US$12.06
US$39.00
+223.4%
35.3%US$60.00US$24.00US$3.966
May ’24US$5.28
US$43.00
+714.4%
34.6%US$66.00US$24.00US$9.986
Apr ’24US$4.98
US$45.43
+811.8%
33.0%US$66.00US$24.00US$11.737
Mar ’24US$5.94
US$49.00
+724.9%
26.8%US$66.00US$36.00US$13.026
Feb ’24US$7.73
US$49.00
+533.8%
26.8%US$66.00US$36.00US$12.256
Jan ’24US$4.83
US$51.00
+955.9%
23.3%US$66.00US$36.00US$8.146
Dec ’23US$5.22
US$51.00
+876.1%
23.3%US$66.00US$36.00US$7.016
Nov ’23US$5.22
US$61.00
+1,069.1%
11.9%US$72.00US$48.00US$6.316

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

Collegium Pharmaceutical

US$980.7m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.96

7D

1.3%

1Y

15.1%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$56.91

7D

0.6%

1Y

9.8%